News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Both ORCL and ADBE are on the reporting docket this week, helping kick off the Q3 cycle. What can investors expect?
Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater
The video game retailer posted net income of $298.7 million in its fiscal second quarter, up from $168.6 million a year earlier
The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28
The earnings report for Nvidia, the world's most valuable company, could have huge economic ramifications.
HSBC has increased its 2026 year-end price target for the S&P 500 to 8,100, citing strong corporate earnings growth and persistent investment in artificial intelligence.
Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.
Q3 earnings season, led by energy and AI-driven tech gains, is likely to beat lowball consensus estimates, with S&P 500 outperformance possibly pushing the index toward 8,500 by early 2027.
Moby summary of United Natural Foods, Inc.'s Q4 2026 earnings call
Moby summary of Gamehaus Holdings Inc.'s Q4 2026 earnings call
Moby summary of ABM Industries Incorporated's Q3 2026 earnings call
S&P 500 companies' second-quarter earnings growth continues to outpace early forecasts as the report
WAFD's EverBank merger targets 29% EPS accretion in 2027, a broader deposit base, and a larger, more diversified commercial banking model.
Ciena posted record numbers, the stock fell anyway, and one big bank is telling clients to buy.
Chewy heads into Q2 earnings with Autoship, healthcare and ad growth supporting momentum, while cautious spending and higher delivery costs pose risks.
PATH's 24% post-earnings slide contrasts with a revenue beat, raised annual guidance and stronger profitability, creating a potential entry point.
RH's Q2 performance may reflect modest sales growth as housing weakness, sourcing disruptions and international startup costs weigh on results.
GameStop on Tuesday posted a second-quarter profit of $298.7 million, compared with $168.6 million a year earlier. The videogame retailer’s net income came within the forecast range it had given last month.
Oracle (ORCL) is reporting quarterly earnings results on Thursday. Bloomberg Intelligence senior technology credit analyst Robert Schiffman shares what investors should be keeping an eye on in the earnings print, especially from a debt-issuance perspective.
NIO narrowed losses 89% as deliveries surged 49% across its three brands.
Salesforce just posted an earnings beat that sent the stock surging 34%, but the source of that surprise raises questions every investor should answer before buying in at these levels.
One Wall Street analyst just put a number on Broadcom that sits far above where the stock trades today.
Tech stock coverage for the week of Sept. 7.
Solaris Energy Infrastructure, Inc. (NYSE:SEI) shares rose 6% on Tuesday after the company increased its Adjusted EBITDA guidance for the third and fourth quarters of 2026 and issued an initial forecast for the first quarter of 2027.
Despite making progress restoring global operations, the device maker said in a securities filing that it is unlikely to meet third-quarter and full-year sales and earnings forecasts.
Boston Scientific (BSX) identified a cybersecurity incident affecting certain information technology
Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.
Boston Scientific said it likely won’t meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.